Insulin degludec
Insulin degludec has been studied in 6 papers since 2021: 1 trial and 1 observational study in people, 4 reviews; 2 in the past year. The newest paper, Oct 19, 2026: “Cardiovascular Outcomes of Insulin Degludec Versus Insulin Glargine in Trial-Eligible and Ineligible Populations: A DEVOTE-Inspired Target Trial Emulation Using the Swedish National Diabetes Register”.
“In the trial-eligible cohort, degludec was associated with a similar risk of MACE compared with glargine”
- 1 lab in 1 country
- 1 finding against
- 4 trials, none about aging
- Human trial1
- Humans1
What did studies of Insulin degludec find?
1Studies of Insulin degludec measured 1 outcome; the most studied are major adverse cardiovascular events (1 study).
Major adverse cardiovascular events
no changein humans1RR 1.1
1 study
Major adverse cardiovascular events
no changein humans1RR 1.1
Insulin degludec has no effect on major adverse cardiovascular events in humans (RR 1.10, 95% CI 0.91-1.34).
“In the trial-eligible cohort, degludec was associated with a similar risk of MACE compared with glargine”
HumansTrial-eligible individuals with type 2 diabetes; compared with insulin glargine
Diabetes, obesity & metabolism
What is Insulin degludec linked with?
2Studies link Insulin degludec with 2 measures, most often major adverse cardiovascular events (1 study) and mortality (1).
Major adverse cardiovascular events
downin humans1RR 0.8
1 study
Major adverse cardiovascular events
downin humans1RR 0.8
Insulin degludec is associated with major adverse cardiovascular events in humans (RR 0.80, 95% CI 0.67-0.95).
“In the trial-ineligible emulation cohort, degludec was associated with lower risks of MACE”
HumansTrial-ineligible individuals with type 2 diabetes; compared with insulin glargine
Diabetes, obesity & metabolism
Mortality
downin humans1RR 0.75
1 study
Mortality
downin humans1RR 0.75
Insulin degludec is associated with mortality in humans (RR 0.75, 95% CI 0.62-0.92).
“but a significantly lower risk of all-cause mortality (risk ratio: 0.75; 95% CI: 0.62-0.92; p = 0.002).”
HumansTrial-eligible individuals with type 2 diabetes; compared with insulin glargine
Diabetes, obesity & metabolism
Who is developing Insulin degludec?
1 company: Tonghua Dongbao Pharmaceutical.
- Companies
- Tonghua Dongbao PharmaceuticalPhase 3type 2 diabetes
Trial sponsors
Company1 trialPhase 4343 people
Tonghua Dongbao Pharmaceutical
Company2 trialsPhase 3554 people
Company1 trialPhase 1121 people